Bulletin from extraordinary general meeting of S2Medical AB (publ)

The extraordinary general meeting of S2Medical AB (publ), registration number 556934-8344 (the "Company") took place today, 14 April 2022. The extraordinary general meeting was held without physical presence by the shareholders exercising their voting rights only by postal vote. The meeting resolved on all proposed matters in accordance with the board of directors previously published proposals. The following is a summary of the main resolutions passed.

Amendment to the articles of association

The meeting resolved to amend the provisions of Article 4 and Article 5 of the articles of association as follows:

§ 4 Share capital

The share capital shall not be less than SEK 1,460,000 and no more than SEK 5,840,000.

§5 Number of shares

The number of shares shall not be less than 25,000,000 and not more than 100,000,000.

Approval of the board of directors’ decision on a rights issue

The extraordinary general meeting approved the board’s resolution from the 15 March 2022 to carry out a rights issue of units:

• The rights issue consists of not more than 15 052 083 units, each unit shall contain one (1) class B share and one (1) warrant of series TO1.

• The Company’s share capital may be increased by a maximum of SEK 881,682.474881 through the issue of not more than 15,052,083 class B shares. Not more than 15,052,083 warrants of series TO1 shall be issued, increasing the share capital upon exercise by a maximum of SEK 881,682.474881. 

• The subscription price shall be SEK 2,00 per unit, corresponding to SEK 2,00 per share. The warrants shall be issued free of charge.

• The right to subscribe for units shall be granted with preferential rights to those who are registered shareholders in the Company on the record date for the issue, whereby the holding of one (1) share entitles the holder to one (1) unit right. One (1) unit right shall entitle the holder to subscribe for one (1) class B share and one (1) warrant of series TO1. 

• Subscription for units shall take place during the period from 22 April 2022 until 6 May 2022. 

• Each warrant of series TO1 entitles the holder to subscribe for one (1) new class B share at a subscription price of corresponding to 70 per cent of the volume-weighted average price of the Company’s B-share on Nasdaq First North Growth Market during the period 22 August 2022 up until and including 30 September 2022. New subscriptions for class B shares through the exercise of the warrants of series TO1 may be made during the period from 6 October 2022 to 20 October 2022.

Authorising to make minor adjustments

The extraordinary general meeting authorised the board of directors, the CEO or any other person appointed by the board of directors to make such minor adjustments and clarifications to the resolutions adopted by the extraordinary general meeting as may be necessary for the registration of the resolutions.

The information was submitted for publication, through the agency of the contact person, on 14-04-2022 14:54 CET.

Contact Details
Petter Sivlér – CEO, S2Medical AB (publ)
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se

Certified Adviser
Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se 
E-mail: ca@vatorsec.se

About S2Medical 

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084